Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Clinical trial NCT05330143 · COMPLETED

Trial details

NCT number: NCT05330143
Sponsor: Ascletis Pharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

HIV-1-infection HIV Infections PD-L1 Gene Mutation

Start date: 2022-06-28
Primary completion: 2024-05-15
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.